{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:34:41Z","timestamp":1759365281728,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.urolonc.2025.07.001","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:22:25Z","timestamp":1753701745000},"page":"654-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging DNA repair deficiency to personalize radiopharmaceutical therapy in prostate cancer"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-1517","authenticated-orcid":false,"given":"Panagiotis J.","family":"Vlachostergios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.urolonc.2025.07.001_bib0001","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2025.07.001_bib0002","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eururo.2018.09.040","article-title":"Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects","volume":"76","author":"Isaacsson Velho","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.07.001_bib0003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2020.05.001","article-title":"Radium-223 in patients with metastatic CRPC harboring DNA damage repair gene defects","volume":"136","author":"van der Doelen","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.07.001_bib6","article-title":"Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium 223: Princess Margaret Cancer Centre (PMCC) experience","volume":"S1078-1439(25)00220-0","author":"Al-Ezzi","year":"2025","journal-title":"Urol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.07.001_bib8","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3390\/cancers16081510","article-title":"Synergistic activity of DNA damage response inhibitors in combination with radium-223 in prostate cancer","volume":"16","author":"Dunne","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.urolonc.2025.07.001_bib0004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2025.07.001_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-22-0583","article-title":"A phase I study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE)","volume":"22","author":"Pan","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"10.1016\/j.urolonc.2025.07.001_bib0005","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1158\/1078-0432.CCR-21-0063","article-title":"Atezolizumab with or without radium-223 dichloride in metastatic castration-resistant prostate cancer: a randomized phase 1b\/2 trial","volume":"27","author":"Fong","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2025.07.001_bib7","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2326-6066.CIR-22-0306","article-title":"Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer","volume":"12","author":"Choudhury","year":"2024","journal-title":"Cancer Immunol Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:14:14Z","timestamp":1759299254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1078143925002492"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging DNA repair deficiency to personalize radiopharmaceutical therapy in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.06.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}